OCT3 polymorphisms and reduced hepatic OCT3 expression, caused by cholestasis and liver fibrosis, lead to reduced metformin uptake, thereby impacting its therapeutic action through changed pharmacokinetics7,16,17. The gene discussed is SLC22A3; the disease is Hepatic fibrosis.